RNA vs. PTCT, CYTK, CNST, ZGNX, ORIC, BGNE, RDY, CTLT, QGEN, and PCVX
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include PTC Therapeutics (PTCT), Cytokinetics (CYTK), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), ORIC Pharmaceuticals (ORIC), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Qiagen (QGEN), and Vaxcyte (PCVX). These companies are all part of the "medical" sector.
PTC Therapeutics (NASDAQ:PTCT) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
PTC Therapeutics received 403 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 65.28% of users gave Avidity Biosciences an outperform vote while only 61.82% of users gave PTC Therapeutics an outperform vote.
PTC Therapeutics currently has a consensus price target of $36.64, suggesting a potential upside of 7.49%. Avidity Biosciences has a consensus price target of $44.29, suggesting a potential downside of 8.01%. Given Avidity Biosciences' higher probable upside, equities analysts clearly believe PTC Therapeutics is more favorable than Avidity Biosciences.
PTC Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Avidity Biosciences has lower revenue, but higher earnings than PTC Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics has a net margin of -62.45% compared to PTC Therapeutics' net margin of -2,103.78%. Avidity Biosciences' return on equity of 0.00% beat PTC Therapeutics' return on equity.
In the previous week, Avidity Biosciences had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 11 mentions for Avidity Biosciences and 10 mentions for PTC Therapeutics. Avidity Biosciences' average media sentiment score of 0.79 beat PTC Therapeutics' score of 0.46 indicating that PTC Therapeutics is being referred to more favorably in the media.
Summary
PTC Therapeutics and Avidity Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
